Astra and Daiichi beat Gilead to the punch, at least in one setting.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
BPI-572270 enters clinical trials.
A new company will develop “next-generation mRNA” projects, amid another mRNA setback.
Persevera is a bust, but Roche hasn’t given up on the front line.
But it will be up to doctors whether to use the combo in Darzalex-exposed patients.
The company pays $2.5bn for Day One and its approved drug Ojemda.
Ono's antisense therapy is to begin its first pivotal trial.
